To report on single-center data of an FDA-approved clinical trial on the objective benefits of cochlear implantation and subsequent ipsilateral Electric-Acoustic Stimulation (EAS).Single-center data from a prospective, multicenter clinical trial.Eighteen subjects completed the 12-month EAS evaluation and were included in this evaluation. Each patient underwent cochlear implantation using a standardized hearing preservation approach. Both hearing preservation and speech perception abilities were evaluated at various intervals. Speech testing included performance measures obtained in quiet (CNC words) and noise (adaptive CUNY protocol) in three listening conditions: hearing aid (HA) alone, cochlear implant (CI) only, and combined ipsilateral EAS.Various levels of hearing preservation were achieved with cochleostomy and round-window surgical approaches in 17 of the 18 subjects. Mean CNC word scores at the 12-month interval were 14.9 ± 12.1, 45.3 ± 15.4, and 70.7 ± 11.7

作者：Oliver F, Adunka；Margaret T, Dillon；Marcia C, Adunka；English R, King；Harold C, Pillsbury；Craig A, Buchman

来源：The Laryngoscope 2013 年 123卷 10期